A virus-directed enzyme prodrug therapy (VDEPT) strategy for lung cancer using a CYP2B6/NADPH-cytochrome P450 reductase fusion protein

Cancer Gene Therapy

Volumn 12, Issue 5, 2005, Pages 497-508

  Tychopoulos, Marina ^a   Corcos, Laurent ^a   Genne, Philippe ^b   Beaune, Philippe ^a   De Waziers, Isabelle ^a  

^a INSERM   (France)

^b Oncodesign   (France)

Author keywords

Cyclophosphamide; Lung cancer; P450 based gene therapy; VDEPT

Indexed keywords

ADENOVIRUS VECTOR; CYCLOPHOSPHAMIDE; CYTOCHROME P450 2B6; HEME; HYBRID PROTEIN; MESSENGER RNA; PRODRUG; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE FERRIHEMOPROTEIN REDUCTASE;

ARTICLE; CONTROLLED STUDY; DRUG ACTIVATION; DRUG CYTOTOXICITY; DRUG METABOLISM; ENZYME ACTIVITY; ENZYME THERAPY; FUSION GENE; GENE DIRECTED ENZYME PRODRUG THERAPY; HUMAN; HUMAN CELL; LUNG CANCER; MICROSOME; NONHUMAN; NORTHERN BLOTTING; PRIORITY JOURNAL; PROTEIN EXPRESSION; SPECTROSCOPY; TUMOR CELL; WESTERN BLOTTING;

ADENOVIRIDAE; ANTINEOPLASTIC AGENTS, ALKYLATING; ARYL HYDROCARBON HYDROXYLASES; BASE SEQUENCE; CELL LINE, TUMOR; CYCLOPHOSPHAMIDE; GENETIC VECTORS; HUMANS; LUNG NEOPLASMS; MOLECULAR SEQUENCE DATA; NADPH-FERRIHEMOPROTEIN REDUCTASE; OXIDOREDUCTASES, N-DEMETHYLATING; PRODRUGS; RECOMBINANT FUSION PROTEINS;

MAMMALIA;

EID: 18244404281     PISSN: 09291903     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.cgt.7700817     Document Type: Article

References (48)

1. Springer CJ, Niculescu-Duvaz I. Approaches to gene-directed enzyme prodrug therapy (GDEPT). Adv Exp Med Biol. 2000;465:403-409.
2. Kan O, Kingsman S, Naylor S. Cytochrome P450-based cancer gene therapy: current status. Expert Opin Biol Ther. 2002;2:857-868.
3. Chen L, Waxman DJ. Intratumoral activation and enhanced chemotherapeutic effect of oxazaphosphorines following cytochrome P-450 gene transfer: development of a combined chemotherapy/cancer gene therapy strategy. Cancer Res. 1995;55:581-589.
4. Code EL, Crespi CL, Penman BW, et al. Human cytochrome P4502B6: interindividual hepatic expression, substrate specificity, and role in procarcinogen activation. Drug Metab Dispos. 1997;25:985-993.
5. Gervot L, Rochat B, Gautier JC, et al. Human CYP2B6: expression, inducibility and catalytic activities. Pharmacogenetics. 1999;9:295-306.
6. Sladek NE. Metabolism of oxazaphosphorines. Pharmacol Ther. 1988;37:301-355.
7. Fleming RA. An overview of cyclophosphamide and ifosfamide pharmacology. Pharmacotherapy. 1997;17:146S-154S.
8. Boddy AV, Yule SM. Metabolism and pharmacokinetics of oxazaphosphorines. Clin Pharmacokinet. 2000;38:291-304.
9. Clarke L, Waxman DJ. Oxidative metabolism of cyclophosphamide: identification of the hepatic monooxygenase catalysts of drug activation. Cancer Res. 1989;49:2344-2350.
10. Chang TK, Yu L, Maurel P, et al. Enhanced cyclophosphamide and ifosfamide activation in primary human hepatocyte cultures: response to cytochrome P-450 inducers and autoinduction by oxazaphosphorines. Cancer Res. 1997;57:1946-1954.
11. Hickman JA. Apoptosis induced by anticancer drugs. Cancer Metastasis Rev. 1992;11:121-139.
12. Schwartz PS, Waxman DJ. Cyclophosphamide induces Caspase 9-dependent apoptosis in 9L tumor cells. Mol Pharmacol. 2001;60:1268-1279.
13. Ichikawa T, Petros WP, Ludeman SM, et al. Intraneoplastic polymer-based delivery of cyclophosphamide for intratumoral bioconversion by a replicating oncolytic viral vector. Cancer Res. 2001;61:864-868.
14. Wei MX, Tamiya T, Rhee RJ, et al. Diffusible cytotoxic metabolites contribute to the in vitro bystander effect associated with the cyclophosphamide/cytochrome P450 2B1 cancer gene therapy paradigm. Clin Cancer Res. 1995;1:1171-1177.
15. Freeman SM, Abboud CN, Whartenby KA, et al. The "bystander effect": tumor regression when a fraction of the tumor mass is genetically modified. Cancer Res. 1993;53:5274-5283.
16. Lu AY, Junk KW, Coon MJ. Resolution of the cytochrome P-450-containing omega-hydroxylation system of liver microsomes into three components. J Biol Chem. 1969;244:3714-3721.
17. Estabrook RW, Franklin MR, Cohen B, et al. Biochemical and genetic factors influencing drug metabolism. Influence of hepatic microsomal mixed function oxidation reactions on cellular metabolic control. Metabolism. 1971;20:187-199.
18. Shiraki H, Guengerich FP. Turnover of membrane proteins: kinetics of induction and degradation of seven forms of rat liver microsomal cytochrome P-450, NADPH-cytochrome P-450 reductase, and epoxide hydrolase. Arch Biochem Biophys. 1984;235:86-96.
19. Chen L, Yu LJ, Waxman DJ. Potentiation of cytochrome P450/ cyclophosphamide-based cancer gene therapy by coexpression of the P450 reductase gene. Cancer Res. 1997;57:4830-4837.
20. Yu LJ, Matias J, Scudiero DA, et al. P450 enzyme expression patterns in the NCI human tumor cell line panel. Drug Metab Dispos. 2001;29:304-312.
21. Shet MS, Fisher CW, Holmans PL, et al. Human cytochrome P450 3A4: enzymatic properties of a purified recombinant fusion protein containing NADPH-P450 reductase. Proc Natl Acad Sci USA. 1993;90:11748-11752.
22. Murakami H, Yabusaki Y, Sakaki T, et al. A genetically engineered P450 monooxygenase: construction of the functional fused enzyme between rat cytochrome P450c and NADPH-cytochrome P450 reductase. DNA. 1987;6:189-197.
23. Fisher CW, Shet MS, Estabrook RW. Construction of plasmids and expression in Escherichia coli of enzymatically active fusion proteins containing the heme-domain of a P450 linked to NADPH-P450 reductase. Methods Enzymol. 1996;272:15-25.
24. Fisher CW, Shet MS, Caudle DL, et al. High-level expression in Escherichia coli of enzymatically active fusion proteins containing the domains of mammalian cytochromes F450 and NADPH-P450 reductase flavoprotein. Proc Natl Acad Sci USA. 1992;89:10817-10821.
25. Chun YJ, Shimada T, Guengerich FP. Construction of a human cytochrome P450 1A1: rat NADPH-cytochrome F450 reductase fusion protein cDNA and expression in Escherichia coli, purification, and catalytic properties of the enzyme in bacterial cells and after purification. Arch Biochem Biophys. 1996;330:48-58.
26. Jounaidi Y, Hecht JE, Waxman DJ. Retroviral transfer of human cytochrome F450 genes for oxazaphosphorine-based cancer gene therapy. Cancer Res. 1998;58:4391-4401.
27. Chase M, Chung RY, Chiocca EA. An oncolytic viral mutant that delivers the CYP2B1 transgene and augments cyclophosphamide chemotherapy. Nat Biotechnol. 1998;16:444-448.
28. Lohr M, Hoffmeyer A, Kroger J, et al. Microencapsulated cell-mediated treatment of inoperable pancreatic carcinoma. Lancet. 2001;357:1591-1592.
29. Lohr M, Muller P, Karle P, et al. Targeted chemotherapy by intratumour injection of encapsulated cells engineered to produce CYP2B1, an ifosfamide activating cytochrome P450. Gene Ther. 1998;5:1070-1078.
30. Knowles BB, Howe CC, Aden DP. Human hepatocellular carcinoma cell lines secrete the major plasma proteins and hepatitis B surface antigen. Science. 1980;209:497-499.
31. He TC, Zhou S, da Costa LT, et al. A simplified system for generating recombinant adenoviruses. Proc Natl Acad Sci USA. 1998;95:2509-2514.
32. Belloc C, Baird S, Cosme J, et al. Human cytochromes P450 expressed in Escherichia coli: production of specific antibodies. Toxicology. 1996;106:207-219.
33. Omura T, Sato R. The carbon monoxide-binding pigment of liver microsomes. I. Evidence for its hemoprotein nature. J Biol Chem. 1964;239:2370-2378.
34. Yasukochi Y, Okita RT, Masters BS. Comparison of the properties of detergent-solubilized NADPH-cytochrome P-450 reductases from pig liver and kidney. Immunochemical, kinetic, and reconstitutive properties. Arch Biochem Biophys. 1980;202:491-498.
35. Habig WH, Pabst MJ, Fleischner G, et al. The identity of glutathione S-transferase B with ligandin, a major binding protein of liver. Proc Natl Acad Sci USA. 1974;71:3879-3882.
36. Bostian KA, Betts GF. Kinetics and reaction mechanism of potassium-activated aldehyde dehydrogenase from Saccharomyces cerevisiae. Biochem J. 1978;173:787-798.
37. Vasiliou V, Pappa A, Petersen DR. Role of aldehyde dehydrogenases in endogenous and xenobiotic metabolism. Chem Biol Interactions. 2000;129:1-19.
38. Omura T, Sato R. A new cytochrome in liver microsomes. J Biol Chem. 1962;237:1375-1376.
39. McMillan K, Bredt DS, Hirsch DJ, et al. Cloned, expressed rat cerebellar nitric oxide synthase contains stoichiometric amounts of heme, which binds carbon monoxide. Proc Natl Acad Sci USA. 1992;89:11141-11145.
40. Miura Y, Fulco AJ. Omega-2) hydroxylation of fatty acids by a soluble system from bacillus megaterium. J Biol Chem. 1974;249:1880-1888.
41. Barnes HJ, Arlotto MP, Waterman MR. Expression and enzymatic activity of recombinant cytochrome P450 17 alpha-hydroxylase in Escherichia coli. Proc Natl Acad Sci USA. 1991;88:5597-5601.
42. Black SD, Coon MJ. Structural features of liver microsomal NADPH-cytochrome P-450 reductase. Hydrophobic domain, hydrophilic domain, and connecting region. J Biol Chem. 1982;257:5929-5938.
43. Sakaki T, Shibata M, Yabusaki Y, et al. Expression of bovine cytochrome P450c21 and its fused enzymes with yeast NADPH-cytochrome P450 reductase in Saccharomyces cerevisiae. DNA Cell Biol. 1990;9:603-614.
44. Yuan ZM, Smith PB, Brundrett RB, et al. Glutathione conjugation with phosphoramide mustard and cyclophosphamide. A mechanistic study using tandem mass spectrometry. Drug Metab Dispos. 1991;19:625-629.
45. Giorgianni F, Bridson PK, Sorrentino BP, et al. Inactivation of aldophosphamide by human aldehyde dehydrogenase isozyme 3. Biochem Pharmacol. 2000;60:325-338.
46. Jounaidi Y, Waxman DJ. Use of replication-conditional adenovirus as a helper system to enhance delivery of P450 prodrug-activation genes for cancer therapy. Cancer Res. 2004;64:292-303.
47. Daniel JC, Smythe WR. Gene therapy of lung cancer. Semin Surg Oncol. 2003;21:196-204.
48. Sterman DH, Treat J, Litzky LA, et al. Adenovirus-mediated herpes simplex virus thymidine kinase/ganciclovir gene therapy in patients with localized malignancy: results of a phase I clinical trial in malignant mesothelioma. Hum Gene Ther. 1998;9:1083-1092.